- Home
- LCTX
as 07-26-2024 4:00pm EST
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 192.6M | IPO Year: | N/A |
| Target Price: | $6.50 | AVG Volume (30 days): | 781.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.84 - $1.61 | Next Earning Date: | 08-08-2024 |
| Revenue: | $8,003,000 | Revenue Growth: | -32.48% |
| Revenue Growth (this year): | 39.47% | Revenue Growth (next year): | -28.71% |
Stock Insider Trading Activity of Lineage Cell Therapeutics Inc. (LCTX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Culley Brian M | LCTX | President and CEO | May 24 '24 | Buy | $1.05 | 10,000 | $10,500.00 | 154,842 | SEC Form 4 |
| BAILEY DON M | LCTX | Director | Feb 8 '24 | Buy | $1.04 | 96,155 | $100,001.20 | 158,801 | SEC Form 4 |
| BROADWOOD PARTNERS, L.P. | LCTX | Director10% Owner | Feb 6 '24 | Buy | $0.00 | 0 | $0.00 | 41,666,255 | SEC Form 4 |
| BROADWOOD PARTNERS, L.P. | LCTX | Director10% Owner | Feb 6 '24 | Buy | $1.04 | 6,730,770 | $7,000,000.80 | 41,666,255 | SEC Form 4 |
Latest Lineage Cell Therapeutics Inc. News
LCTX Breaking Stock News: Dive into LCTX Ticker-Specific Updates for Smart Investing
MT Newswires
24 days ago
Lineage Cell Therapeutics Included in Russell 3000 Index
Business Wire
25 days ago
Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index
The Telegraph
2 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Motley Fool
2 months ago
4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
AFP
2 months ago
Seoul resumes loudspeaker propaganda against North
Simply Wall St.
2 months ago
Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss
Simply Wall St.
2 months ago
American Software Full Year 2024 Earnings: EPS Beats Expectations
Simply Wall St.
2 months ago
Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns
Compare LCTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LCTX Lineage Cell Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.